Objective:
To provide in depth evaluation of dogs with AML, including typing cells in blood and bone marrow, and documenting response to therapy. Having sufficient data on a large number of dogs with AML will help to identify which types have a better or worse prognosis.
Background:
Acute myeloid leukemias (AML) are cancers of cells in the bone marrow. Some types of AML progress very quickly and are difficult to treat, while other AMLs are more slowly progressive. AML is challenging to diagnose, and little is known about the prognosis of different types of AML.
Inclusion criteria:
Dogs with a diagnosis of acute myeloid leukemia or myelodysplastic syndrome.
Samples required:
- Blood (~2-3ml)
- Bone marrow aspirate
Client Compensation:
- Reduced costs for bone marrow aspirate/biopsy.
- No costs for molecular tests.
Researchers:
- Dr. Dorothee Bienzele (PI)
Contact:
Vicky Sabine (PhD), Clinical Research Coordinator
- Work Cell #: 226-218-0338
- Email: ovc.clinicaltrials@uoguelph.ca